TipRanks (Tue, 18-Aug 6:01 AM ET)
FDA Feedback Positive for PRAX’s Lead Drugs as Cash Position Surges to $1.4 Billion
Market Chameleon (Thu, 6-Aug 5:40 AM ET)
Globe Newswire (Thu, 6-Aug 8:00 AM ET)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 4-Aug 4:01 PM ET)
Globe Newswire (Thu, 30-Jul 4:01 PM ET)
Globe Newswire (Tue, 7-Jul 8:00 AM ET)
Globe Newswire (Mon, 29-Jun 4:30 PM ET)
Globe Newswire (Mon, 22-Jun 8:00 AM ET)
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Globe Newswire (Thu, 4-Jun 4:01 PM ET)
Praxis Precision Medicines Provides Vormatrigine Program Update
Globe Newswire (Mon, 1-Jun 4:15 PM ET)
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Praxis Precision Medicines trades on the NASDAQ stock market under the symbol PRAX.
As of August 18, 2026, PRAX stock price declined to $370.25 with 174,560 million shares trading.
PRAX has a beta of 2.82, meaning it tends to be more sensitive to market movements. PRAX has a correlation of 0.06 to the broad based SPY ETF.
PRAX has a market cap of $10.34 billion. This is considered a Large Cap stock.
In the last 3 years, PRAX traded as high as $391.64 and as low as $13.01.
The top ETF exchange traded funds that PRAX belongs to (by Net Assets): VTI, IWM, VB, XBI, VBR.
PRAX has outperformed the market in the last year with a price return of +686.4% while the SPY ETF gained +20.5%. PRAX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.1% and +21.2%, respectively, while the SPY returned +4.1% and +1.3%, respectively.
PRAX support price is $362.25 and resistance is $390.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRAX shares will trade within this expected range on the day.
